Immunai Announces Agreement to advance an Inflammatory Bowel Disease Target with AstraZeneca

​Immunai, a leading AI biotech company specializing in mapping the human immune system, today announced an agreement with AstraZeneca for the development of a target for inflammatory bowel disease (IBD). The target was identified through Immunai’s Immunodynamics Engine (IDE™), built on its proprietary immune cell atlas, AMICA™.

Under the terms of the agreement, AstraZeneca will gain exclusive rights to develop and commercialize therapeutics directed at the target. Immunai will receive an upfront payment and is eligible to receive up to $85m in total consideration.

The target was discovered using Immunai’s platform, which integrates clinically annotated single-cell multi-omics datasets with machine learning to model immune function and dysfunction across disease states. The platform is designed to enable rapid, scalable identification of immune-modulating targets across a range of indications, including oncology, autoimmunity, and inflammatory disorders.

“Target discovery has always been a challenging process, especially in complex immune diseases like IBD. Using an unbiased approach powered by AI and machine learning, Immunai’s platform has identified an exciting novel target for IBD. This remains a debilitating condition for millions, and despite existing therapies, many patients continue to face uncontrolled symptoms, hospitalizations, and progressive complications,” said Noam Solomon, PhD, co-founder and CEO of Immunai. “This agreement marks a turning point. By modeling the immune system with high-resolution single-cell data and artificial intelligence, we’re not only finding new targets, we’re beginning to understand why they matter. We’re proud to expand our collaboration with AstraZeneca as we work together to discover and develop new therapies.”

This milestone builds on a multi-year collaboration between the two companies which began in 2022. In 2024, AstraZeneca committed $18 million to leverage Immunai’s proprietary platform and machine learning capabilities to inform certain oncology clinical trials. The collaboration is focused on clinical decision-making, including dose selection, elucidating mechanisms of action, patient responder vs. non-responder analysis, and biomarker identification, using Immunai’s IDE.

For more information about Immunai, please visit immunai.com.

About Immunai
Immunai uses single-cell genomics and machine learning to discover and improve development of novel therapeutics by decoding the immune system. The team of185 employees, 85 of whom are PhDs or MDs, is composed of experts in genomics, machine learning, bioinformatics, immunology, and software engineering. The company has more than 30 partnerships with Fortune 100 pharmaceutical companies and leading academic institutions. Headquartered in New York City, with offices in Tel Aviv, Zurich, Prague, the company has raised close to $270M in funding to-date. For more information visit www.immunai.com.

Contact Information

Emma McDermott

PR for Immunai

VSC for Immunai

Contact via E-mail